Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Health Progress (Saint Louis, Mo.)
|
February 6, 1998
The evolving nature of sponsorship. Recent decades have brought changes both in theory and practice
B K Dunn
Annals of the New York Academy of Sciences
|
January 25, 2002
Cancer treatment and prevention: introduction
B K Dunn, B Kramer
Annals of the New York Academy of Sciences
|
January 25, 2002
The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1)
N Wolmark, B K Dunn
Annals of the New York Academy of Sciences
|
January 25, 2002
Opportunities for future research
S Sherman, B K Dunn
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2000
Breast cancer prevention: results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) breast cancer prevention trial (NSABP P-1: BCPT)
B K Dunn, L G Ford
The Breast Journal
|
July 27, 2001
From adjuvant therapy to breast cancer prevention: BCPT and STAR
B K Dunn, L G Ford
Annals of the New York Academy of Sciences
|
January 25, 2002
What would be the properties of an ideal SERM?
M Anthony, J K Williams, B K Dunn
Annals of the New York Academy of Sciences
|
January 25, 2002
Defining benefits and risks for SERMs in clinical trials and clinical practice
S R Johnson, B K Dunn, M Anthony
Hematology/Oncology Clinics of North America
|
January 15, 1999
Phase III, large-scale chemoprevention trials. Approach to chemoprevention clinical trials and phase III clinical trial of tamoxifen as a chemopreventive for breast cancer--the US National Cancer Institute experience
B K Dunn, B S Kramer, L G Ford
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2000
Breast cancer prevention: the next steps
B K Dunn, W McCaskill-Stevens, L G Ford
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Health Progress (Saint Louis, Mo.)
|
February 6, 1998
The evolving nature of sponsorship. Recent decades have brought changes both in theory and practice
B K Dunn
Annals of the New York Academy of Sciences
|
January 25, 2002
Cancer treatment and prevention: introduction
B K Dunn, B Kramer
Annals of the New York Academy of Sciences
|
January 25, 2002
The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1)
N Wolmark, B K Dunn
Annals of the New York Academy of Sciences
|
January 25, 2002
Opportunities for future research
S Sherman, B K Dunn
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2000
Breast cancer prevention: results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) breast cancer prevention trial (NSABP P-1: BCPT)
B K Dunn, L G Ford
The Breast Journal
|
July 27, 2001
From adjuvant therapy to breast cancer prevention: BCPT and STAR
B K Dunn, L G Ford
Annals of the New York Academy of Sciences
|
January 25, 2002
What would be the properties of an ideal SERM?
M Anthony, J K Williams, B K Dunn
Annals of the New York Academy of Sciences
|
January 25, 2002
Defining benefits and risks for SERMs in clinical trials and clinical practice
S R Johnson, B K Dunn, M Anthony
Hematology/Oncology Clinics of North America
|
January 15, 1999
Phase III, large-scale chemoprevention trials. Approach to chemoprevention clinical trials and phase III clinical trial of tamoxifen as a chemopreventive for breast cancer--the US National Cancer Institute experience
B K Dunn, B S Kramer, L G Ford
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2000
Breast cancer prevention: the next steps
B K Dunn, W McCaskill-Stevens, L G Ford
Page
of 2